Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy

MLA

Holman, Robert C., et al. “Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy.” Journal of Infectious Diseases, vol. 184, no. 11, Dec. 2001, p. 1437. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.81102688&authtype=sso&custid=ns315887.

APA

Holman, R. C., Paddock, C. D., Curns, A. T., Krebs, J. W., McQuiston, J. H., & Childs, J. E. (2001, December 1). Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy. Journal of Infectious Diseases, 184(11), 1437.

Chicago

Holman, Robert C., Christopher D. Paddock, Aaron T. Curns, John W. Krebs, Jennifer H. McQuiston, and James E. Childs. 2001. “Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy.” Journal of Infectious Diseases, December 1. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.81102688&authtype=sso&custid=ns315887.